AI Article Synopsis

  • The study documents four cases where patients developed new or worsened uveitis after receiving infliximab treatment.
  • The patients included three women with a mean age of 33, and they were treated for various conditions like rheumatoid arthritis and Crohn’s disease.
  • All cases saw improvement in ocular inflammation after discontinuing infliximab and adding other treatments, suggesting that these adverse effects are rare but significant.

Article Abstract

Objective: To report four cases of new onset or exacerbation of uveitis following administration of infliximab.

Methods: This retrospective observational case series includes four patients who developed new onset or exacerbation of uveitis paradoxically during infliximab treatment.

Results: Four patients were assessed, including three women, with a mean age of 33 (14-84) years. Infliximab was introduced for the treatment of scleritis associated with rheumatoid arthritis (two cases), chronic anterior uveitis associated with juvenile idiopathic arthritis (JIA) (one case) and Crohn's disease (one case). Anterior scleritis associated with rheumatoid arthritis successfully improved following infliximab administration; however, macular oedema or dense vitritis paradoxically developed in two cases. In one case, infliximab was switched to tocilizumab. In another case, infliximab was discontinued, and additional corticosteroids and immunosuppressive medications were added. In one patient with JIA, new-onset macular oedema and exacerbation of anterior uveitis were observed during infliximab treatment, so the patient was switched to adalimumab. In the patient with Crohn's disease treated with infliximab, severe vasculitis and macular oedema occurred, requiring intravitreal triamcinolone injection. The patient was switched to adalimumab. Given that these reactions were paradoxical effects of infliximab, infliximab treatment was discontinued in all cases, and additional corticosteroids or immunosuppressive medications were added. All cases remained free of ocular inflammation at the last visit.

Conclusion: Uveitis rarely occurs de novo or is exacerbated during infliximab treatment. Cessation of infliximab led to resolution of this paradoxical adverse effect.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615868PMC
http://dx.doi.org/10.1136/bmjophth-2018-000250DOI Listing

Publication Analysis

Top Keywords

onset exacerbation
12
exacerbation uveitis
12
infliximab
12
macular oedema
12
infliximab treatment
12
scleritis associated
8
associated rheumatoid
8
rheumatoid arthritis
8
anterior uveitis
8
crohn's disease
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!